Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dopamine receptors labelled by PHNO

P Seeman1, C Ulpian, R D Larsen

  • 1Department of Pharmacology, University of Toronto, Ontario, Canada.

Synapse (New York, N.Y.)
|August 1, 1993
PubMed
Summary

Researchers developed a new radioactive tracer, [3H](+)PHNO, to label dopamine D2 receptors. This tracer shows high affinity and selectivity for the high-affinity state, crucial for diagnosing psychomotor diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biallelic variants in the SORD gene are one of the most common causes of hereditary neuropathy among Czech patients.

Scientific reports·2021
Same author

Demyelinating Charcot-Marie-Tooth neuropathy associated with FBLN5 mutations.

European journal of neurology·2020
Same author

Novel SBF2 mutations and clinical spectrum of Charcot-Marie-Tooth neuropathy type 4B2.

Clinical genetics·2018
Same author

Charcot-Marie-Tooth 1A: Heterozygous T118M Mutation over a CMT1A Duplication Has No Influence on the Phenotype.

Annals of the New York Academy of Sciences·2017
Same author

Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose.

Translational psychiatry·2016
Same author

Treatment Outcome of Patients With Early Stage Cervical Cancer Treated With Laparotomy Compared to Robotically-Assisted Laparoscopic Approach.

Journal of minimally invasive gynecology·2016

Area of Science:

  • Neuroscience
  • Radiopharmaceutical Chemistry
  • Pharmacology

Background:

  • Abnormalities in the high-affinity state of dopamine D2 receptors are implicated in psychomotor diseases.
  • A selective radioactive agonist is needed to label this receptor state for potential clinical diagnostics.
  • (+)PHNO is a known D2 agonist used in Parkinson's disease treatment.

Purpose of the Study:

  • To synthesize and characterize a novel radioligand, [3H](+)PHNO, for labeling the high-affinity state of dopamine D2 receptors.
  • To evaluate the potential of [3H](+)PHNO for clinical diagnostic applications in psychomotor diseases.

Main Methods:

  • Synthesis of [3H](+)PHNO from allyl-des-propyl(+)PHNO.
  • In vitro binding assays using homogenates of canine brain striata.
  • Determination of dissociation constants (Kd) in the presence and absence of NaCl.
  • Competition binding studies with known dopamine agonists and antagonists.
  • Assessment of binding specificity and influence of guanylylimidodiphosphate.

Main Results:

  • [3H](+)PHNO exhibited high affinity for dopamine D2 receptors (Kd = 0.35 nM without NaCl, 0.56 nM with NaCl).
  • Binding was inhibited by D2-selective ligands, not D4 ligands, indicating D2 receptor specificity.
  • Guanilylimidodiphosphate significantly inhibited binding, confirming preferential binding to the high-affinity D2 state.
  • Binding site density was higher than [3H]spiperone, suggesting binding to D2 monomers.
  • The radioligand showed sensitivity to endogenous dopamine, requiring lower dissociation constants for in vivo use.

Conclusions:

  • [3H](+)PHNO is a selective and high-affinity radioligand for the high-affinity state of dopamine D2 receptors.
  • The tracer demonstrates potential for labeling D2 receptors in psychomotor disease research.
  • Further development is needed to create a [3H]ligand with lower dissociation constants for effective in vivo imaging.

Related Experiment Videos